Cipaglucosidase alfa 105mg powder for solution for infusion vials
NHS hospitals in England used £17,103,723 of indicative cost of Cipaglucosidase alfa 105mg powder for solution for infusion vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 3.5% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Cipaglucosidase alfa 105mg powder for solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Cipaglucosidase alfa 105mg powder for solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Salford Royal Nhs Foundation Trust | £7,626,549 |
| University College London Foundation Tr | £5,077,128 |
| Cambridge Univ Hosp Nhs Foundation Trust | £2,907,702 |
| Royal Free London Nhs Foundation Trust | £1,421,280 |
| Univ Hpl B/Ham Nhs Foundation Trust | £71,064 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.